gemcitabine has been researched along with vitamin d 2 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fetterly, G; Fountzilas, C; Iyer, R; Javle, M; Johnson, C; Ma, Y; Tan, W | 1 |
| Amin, M; Bansod, S; Boice, N; Brown, A; Grierson, PM; Lim, KH; Liu, J; Park, H; Pedersen, KS; Suresh, R; Tan, B; Trikalinos, NA; Wang-Gillam, A | 1 |
1 review(s) available for gemcitabine and vitamin d 2
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for gemcitabine and vitamin d 2
| Article | Year |
|---|---|
A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Ergocalciferols; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2018 |
1 other study(ies) available for gemcitabine and vitamin d 2
| Article | Year |
|---|---|
A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ergocalciferols; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Pilot Projects | 2023 |